Interleukin-12-expressing oncolytic virus: A promising strategy for cancer immunotherapy  by Alkayyal, Almohanad A. et al.
Taibah University
Journal of Taibah University Medical Sciences (2016) 11(3), 187e193Journal of Taibah University Medical Sciences
www.sciencedirect.comReview ArticleInterleukin-12-expressing oncolytic virus: A promising strategy for
cancer immunotherapy
Almohanad A. Alkayyal, MSc b, Ahmad B. Mahmoud, MSc c and
Rebecca C. Auer, MD a,*
aCentre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Canada
bDepartment of Medical Laboratory Technology, University of Tabuk, Tabuk, KSA
cCollege of Applied Medical Sciences, Taibah University, Almadinah Almunawwarah, KSAReceived 5 March 2016; revised 29 March 2016; accepted 2 April 2016; Available online 27 April 2016ﺺﺨﻠﻤﻟﺍ
ﺓﺩﺎﻀﻤﻟﺍﺓﺮﻜﺘﺒﻤﻟﺍﺕﺎﺟﻼﻌﻟﺍﻉﺍﻮﻧﺃﻦﻣﻲﻫ؛ﺔﻴﻧﺎﻃﺮﺴﻟﺍﻡﺍﺭﻭﻸﻟﺔﻠﺗﺎﻘﻟﺍﺕﺎﺳﻭﺮﻴﻔﻟﺍ
ﺎﻳﻼﺨﻟﺎﺑﺱﺎﺴﻤﻟﺍﻥﻭﺩﺔﻴﺋﺎﻘﺘﻧﺎﺑﺔﻴﻧﺎﻃﺮﺴﻟﺍﺔﺠﺴﻧﻷﺍﺮﻣﺪﺗﻭﻑﺪﻬﺘﺴﺗﻲﺘﻟﺍ،ﻥﺎﻃﺮﺴﻠﻟ
ﻦﻣﺪﻳﺰﻤﻠﻟﻡﺎﻤﺘﻫﻻﺍﻦﻣﺪﻳﺰﻤﻟﺍﺔﻠﺗﺎﻘﻟﺍﺕﺎﺳﻭﺮﻴﻔﻟﺎﺑﻡﺍﺭﻭﻷﺍﺝﻼﻋﺐﺴﺘﻛﺍ.ﺔﻤﻴﻠﺴﻟﺍ
ﺔﻴﻜﻳﺮﻣﻷﺍﺀﺍﻭﺪﻟﺍﻭﺀﺍﺬﻐﻟﺍﺓﺭﺍﺩﺇﺔﻘﻓﺍﻮﻣﺪﻌﺑﻲﻋﺎﻨﻤﻟﺍﺝﻼﻌﻟﺍﻦﻣﺪﻳﺪﺟﻉﻮﻨﻛﺭﻮﻄﺘﻟﺍ
ﻲﻠﻤﻌﻟﺍﺞﻬﻨﻟﺍﻡﻮﻘﻳﻭ.ﻡﺪﻘﺘﻤﻟﺍﻲﻨﻴﻧﻼﻤﻟﺍﻡﺭﻮﻟﺍﺝﻼﻌﻟﺲﺑﺮﻬﻟﺍﺱﻭﺮﻴﻓﻰﻠﻋﺍﺮﺧﺆﻣ
ﺢﻴﻠﺴﺗﻰﻠﻋﺔﻴﻧﺎﻃﺮﺴﻟﺍﻡﺍﺭﻭﻸﻟﺔﻠﺗﺎﻘﻟﺍﺕﺎﺳﻭﺮﻴﻔﻠﻟﺔﻴﻠﻋﺎﻔﻟﺍﻦﻣﺭﺪﻗﻰﺼﻗﺃﻖﻴﻘﺤﺘﻟ
ﺓﺭﺪﻘﻟﺍﺰﻳﺰﻌﺗﻰﻠﻋﺓﺭﺩﺎﻗﻥﻮﻜﺘﻟ،ﺔﻋﺎﻨﻤﻠﻟﺓﺯﺰﻌﻤﻟﺍﺰﻨﻳﺎﻛﻮﺘﻳﺎﺴﻟﺎﺑﺕﺎﺳﻭﺮﻴﻔﻟﺍ
٢١-ﻦﻛﻮﻴﻟﺮﺘﻧﺍﻒﻴﻨﺼﺗﻢﺗﺪﻗﻭ.ﺔﻴﻠﻋﺎﻔﺑﺔﻴﻧﺎﻃﺮﺴﻟﺍﺎﻳﻼﺨﻟﺍﻰﻠﻋﻡﻮﺠﻬﻠﻟﺔﻴﻋﺎﻨﻤﻟﺍ
ﺯﺎﻬﺠﻟﺍﻦﻣﻼﻛﻂﻴﺸﻨﺘﺑﻡﻮﻘﺗ٬ﺔﻠﻋﺎﻓﻡﺍﺭﻭﻸﻟﺓﺩﺎﻀﻣﺔﻄﺸﻧﺃﻪﻟﻱﻮﻗﺰﻨﻳﺎﻛﻮﺘﻳﺎﺳﺎﻛ
ﻥﺃﺕﺎﺳﺍﺭﺪﻟﺍﻦﻣﺪﻳﺪﻌﻟﺍﺕﺮﻬﻇﺃﻭ.ﻡﺍﺭﻭﻸﻟﺩﺎﻀﻤﻟﺍﻲﻔّﻴَﻜَﺘﻟﺍﻭﻱﺮﻄِﻔﻟﺍﻲﻋﺎﻨﻤﻟﺍ
ﺮﺷﺆﻣﻦﺴﺤﻳ،ﺔﻴﻧﺎﻃﺮﺴﻟﺍﻡﺍﺭﻭﻸﻟﺔﻠﺗﺎﻘﻟﺍﺕﺎﺳﻭﺮﻴﻔﻟﺍﺺﺋﺎﺼﺧﻱﺫ٢١-ﻦﻛﻮﻴﻟﺮﺘﻧﺍ
٬ﺔﻴﻋﺬﺠﻟﺍﺎﻳﻼﺨﻟﺍﻒﻴﻇﻮﺗﻭﻂﻴﺸﻨﺗﺔﻄﺳﺍﻮﺑﺔﻳﺮﻳﺮﺴﻟﺍﻞﺒﻗﻡﺭﻮﻟﺍﺕﺎﻨﻴﻌﻟﺝﻼﻌﻟﺍ
ﻦﺴﺤﺗﺎﻫﺭﻭﺪﺑﻲﺘﻟﺍﺎﻳﻼﺨﻠﻟﺔﻣﺎﺴﻟﺍ“ﺕ”ﺎﻳﻼﺨﻟﺍﻭﺔﻠﺗﺎﻘﻟﺍﺔﻴﻌﻴﺒﻄﻟﺍﺔﻣﺎﺴﻟﺍﺎﻳﻼﺨﻟﺍﻭ
ﻲﺘﻟﺍﺔﻠﺗﺎﻘﻟﺍﺕﺎﺳﻭﺮﻴﻔﻟﺍﻞﻤﻌﻟﺔﻋﺎﻨﻤﻟﺍﺔﻴﻟﺁﺶﻗﺎﻨﻧ٬ﺽﺮﻌﻟﺍﺍﺬﻫﻲﻓ.ﻡﺭﻮﻟﺍﺔﻟﺍﺯﺇ
.٢١-ﻦﻛﻮﻴﻟﺮﺘﻧﺍﻱﻮﺤﺗ
؛ﺕﺎﺳﻭﺮﻴﻔﻟﺎﺑﺝﻼﻌﻟﺍ؛٢١-ﻦﻛﻮﻴﻟﺮﺘﻧﺍ؛ﻲﻋﺎﻨﻤﻟﺍﺝﻼﻌﻟﺍ:ﺔﻴﺣﺎﺘﻔﻤﻟﺍﺕﺎﻤﻠﻜﻟﺍ
ﻲﻧﺎﻃﺮﺴﻟﺍﻡﺭﻮﻠﻟﻞﺗﺎﻘﻟﺍﺱﻭﺮﻴﻔﻟﺍ؛ﻥﺎﻃﺮﺴﻟﺍ
tcartsbA
levon fo ssalc gnigreme na era )sVO( sesuriv citylocnO
dna tcefni ylevitceles taht stnega cituepareht recnac-itna* Corresponding address: Ottawa General Hospital, 1617 CCW,
Box#134, 501 Smyth Road, Ottawa, Ontario, K1H8L6, Canada.
E-mail: rauer@ohri.ca (R.C. Auer)
Peer review under responsibility of Taibah University.
Production and hosting by Elsevier
1658-3612  2016 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah University. T
(http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.10destroy cancerous tissues without damaging normal cells.
With the recent US Food and Drug Administration
(FDA) approval of Herpes Virus (T-VEC) for the treat-
ment of advanced melanoma, oncolytic virotherapy has
gained more attention for further development as a novel
form of immunotherapy. A viable approach to maximize
the efficacy of OVs involves arming them with immune-
enhancing cytokines that are capable of boosting the
host’s immune response to effectively attack tumour cells.
Interleukin-12 (IL-12) is a powerful cytokine with potent
antitumour activities that activates both innate and
adaptive anti-tumour responses. Several studies have
demonstrated that IL-12-expressing OVs improve the
therapeutic index in pre-clinical tumour models by acti-
vating and recruiting dendritic cells (DCs), cytotoxic
natural killer (NK) cells and cytotoxic T cells, which
subsequently improve tumour clearance. In this review,
the immunological mechanisms of IL-12eexpressing vi-
ruses are discussed.
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One of the most potent alternative cancer treatments is
gene therapy using various agents, such as oncolytic viruses
(OVs), which are viruses that can selectively infect, replicate,
and generate a greater immune response against cancer and
directly kill tumour cells.1 OVs have been used in clinical
trials for the treatment of various cancers, such as
pancreatic cancer, ovarian cancer, colorectal cancer and
glioma.2 OVs are designed to target and hijack cancerous
cell machinery including: (a) pro-apoptotic targeting where
the viruses delay apoptosis of infected cells to promote their
replication for the synthesis and assembly of a large number
of new viruses before killing the infected cancer cell; (b)
transcriptional targeting where an essential viral gene is
placed under the regulation of tumour specific promoters; (c)
transductional targeting where the ability of the tumour cells
to up regulate their tumour-specific receptors is exploited for
specific targeting of cancer cells by OVs, and (d) targeting
strategies based on the tumour microenvironment where
modified microenvironments, such as angiogenesis, hypoxia
and activation of certain proteases are exploited.3 The
infected cancer cells eventually produce more infectious
particles that infect neighbouring cancer cells; thus, the
anti-cancer “infection” spreads.
Direct tumour cytotoxicity appears to be only one of the
key mechanisms mediating the anti- efficacy of OV.4
Interestingly, immune-mediated tumour suppression for
overall OV efficacy is likely influenced by the initial period of
vigorous OV replication and lytic activity, which optimally
set the stage for subsequent antitumour immune response.4,5
Studies have shown that T and NK cell recruitment into
tumours associated with increased survival and enhance
antitumour efficacy, subsequently, genetically modified
viruses coding for immunomodulatory agents, such as
cytokines or chemokines, have come into focus. Such
engineered viruses can promote an efficient anti-tumour
immune response using several mechanisms, including the
induction of intrinsic cellular stress pathways that activate
innate immunity, expression of stress-induced self-ligands
rendering this cell susceptible to natural killer (NK) cell-
mediated lysis and the enhanced presentation of tumour-
specific antigens to cytotoxic CD8þ T cells.6 A milestone
has been achieved in the usage of cytokine-armed oncolytic
viruses when the FDA recently approved talimogene laher-
parepvec (T-VEC), a herpes simplex virus (HSV) expressing
the immunostimulatory cytokine granulocyte-macrophage
colony-stimulating factor (GM-CSF), in the treatment of
patients with metastatic melanoma.7 A number of OVs that
harbour IL-12 have been demonstrated, in which IL-12
significantly enhances the anticancer immune response.
Interleukin-12 (IL-12) is a heterodimeric cytokine produced
primarily by phagocytic cells and antigen-presenting cells in
response to bacteria, bacterial products, and intracellular
parasites. The major target cells of IL-12 action include NK
and T cells, which induce IFN-gamma (IFN-g) production,
cytotoxic activity, increased proliferation in cooperation
with other costimulatory signals, and differentiation of T
helper type 1 (Th1) cells.6 IL-12 is one of the most potent
anti-cancer cytokines. Its antitumoural effect is mediated by
the activity of T, NK, and NKT cells and by an anti-
angiogenic effect. Given its ability to activate both NK andcytotoxic T cells, IL-12 represents the ideal candidate for
tumour immunotherapy in humans.
Unfortunately, systemic administration of IL-12 to cancer
patients causes excessive clinical toxicity and severe side ef-
fects.8 To avoid such severe side effects, scientists have used
novel methods to deliver this cytokine directly to the tumour
site, and one of these methods involves the use of OVs.
Taking advantage of OV oncotropism, OVs appear to be a
promising platform to effectively deliver IL-12 and restrict
it is expression within the tumour microenvironment. The
present review summarizes the most promising IL-12-
expressing OVs as shown in preclinical models and patients.Adenovirus
Adenoviruses belong to the family of Adenoviridae. Their
name is derived from the human adenoid tissues from
which they were first isolated.9 Adenoviruses are non-
enveloped viruses with a genome of double stranded linear
DNA 26e48 kb in size and a capsid of 65e80 nm in diam-
eter.9 The capsid contains penton, hexon and fibre proteins
that are important for the infection of cells by the virus.
The virus uses receptor-mediated endocytosis to enter
cells.10 The first vector systems developed for gene delivery
and expression were derived from adenoviruses.11
Subsequently, adenoviruses have emerged as one of the
most frequently used viral vectors for gene therapies,
including cancer viral therapy.11 This emergence is related
to their ability to affect the metabolic activity of various
cells (replicating and non-replicating cells), host large inser-
ted genes, and code for proteins without incorporating into
the cell genome of the host.11
Various adenovirus mutants, which are capable of killing
tumour cells, have been engineered to utilize tumour-
associated promoters to regulate the expression of essential
viral genes, thus restricting viral replication and spreading to
tumour cells.12 A common strategy in designing oncolytic
adenoviruses is to genetically engineer the adenoviral early
region 1A (E1A).13 This process involves a bondage of the
CR2 region of adenoviral E1A to the retinoblastoma
protein (RB) and other related proteins that regulate the
E2F family of transcription factors, which plays a pivotal
role in the regulation of cellular proliferation and
stimulates the entrance of quiescent cells into the S phase.13
Given that cancerous cells often exhibit a dysfunctional RB
and uncontrolled cell cycle, deletion of the CR2 region
allows the mutant adenovirus to replicate selectively in
tumour cells.14,15
Several adenovirus mutants have been generated to
maximize virus selectivity and efficacy, including mutant
dl1520 (ONYX-015/CI-1042), mutant dl 922e947 and
mutant AdA-24. Mutant dl1520 (ONYX-015/CI-1042) was
the first engineered replication-selective virus used in humans
and has been demonstrated to be an anti-cancer agent in pre-
clinical studies and clinical trials.16 Various studies have
shown that arming oncolytic adenovirus with immune
modulatory cytokines, such as IL-2 and IL-12, induce
enhanced antitumour activity. Expression of the genes
associated with the pre-cited interleukins induces the pro-
duction of cytokines that activate the type-1 immune
response, thus resulting in the regression of the development
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co-expression of IL-12 and 4-1BBL via an oncolytic adeno-
virus significantly enhanced the antitumour and anti-
metastatic effects compared with the expression of the
individual genes coding for either cytokine in a preclinical
study.18 Moreover, their study revealed a synergistic
enhancement in interferon (IFN)-g levels in mice treated
with adenovirus simultaneously expressing IL-12 and 4-
1BBL. The latter study also reported that the increased
antitumour immune response is potentially mediated via the
enhanced cytolytic activity of cytotoxic T lymphocytes
(CTLs) and IFN-g-releasing immune cells. Another study
investigated the antitumoural activity of a recombinant
adenovirus expressing murine IL-12 (AdmIL-12) in a murine
model of prostate cancer and revealed that the tumour
growth was reduced by greater than 50%, whereas the sur-
vival time increased from 23.4 to 28.9 days.19Herpes simplex virus (HSV)
HSV is an enveloped double-stranded DNA virus
belonging to the family of Herpesviridae.20 The virus infects
human cells by fusion of the viral envelope proteins with the
host cell plasma membrane. There are two types of HSV:
HSV1 and HSV2. In the case of HSV-1, three major gene
regions, alpha, beta, and gamma, are present in the genome
and act simultaneously to regulate the entry, replication and
spreading of the virus in host cells.3
To allow a replication of HSV in malignant tumour cells
specifically, a variety of mutants, such as R3616 and G207,
have been designed by inactivating the function of the viral
genes that encode for ribonucleotide reductase, thymidine ki-
nase and infected cell protein 34.5 (ICP34.5).21e23 These
mutants can replicate preferentially in proliferating cancer
cells that exhibit a high endogenous ribonucleotide reductase
activity. Phase I clinical trials using the latter mutants have
revealed an effective therapy in the treatment of malignant
brain tumours.21
The advantage of using oncolytic HSVs as agents for
localized IL-12 delivery, expression, and immunomodulatory
activity relies on the fact that they are tumour specific and
trigger a limited antitumour adaptive immune response.24
Tooba et al. reported the efficiency of G47D-mIL12, a
genetically engineered IL-12-expressing oncolytic HSV, in
the treatment of glioblastoma, an aggressive and fatal adult
brain tumour. Using a murine glioblastoma stem cell (GSC)
model they demonstrated that G47D-mIL12 infects and rep-
licates similar to its unarmed oncolytic HSV counterpart
in vitro, whereas G47D-mIL12 significantly enhances survival
of mice with intracerebral 005 tumours in vivo. The study also
revealed that in addition to targeting GSCs, G47D-mIL12
increases IFN-g release, hinders angiogenesis by inducing IP-
10 protein, and decreases the number of regulatory T cells in
the tumour. G47 armed with immunomodulatory molecules,
such as IL-12, significantly increases the efficacy of oncolytic
HSV-1 therapy in glioma treatment.24Newcastle disease virus (NDV)
NDV, also known as avian paramyxovirus-1 (APMV-1)
belongs to the family of Paramyxoviridae. The genome is asingle-stranded negative-sense RNA that is15 kb long and
contains six genes encoding at least eight proteins, including
six structural (NP, P, M, F, HN, L) and two non-structural
(V and W) proteins.25 NDV accesses the host by first
binding to the cells via the HN protein and acid-containing
host cell receptors. Further fusion of the viral and cell-
surface membranes occurs followed by a release and repli-
cation of the viral RNA into the cytoplasm.26
NDV possesses various properties that make it an excel-
lent anti-tumour agent, including good cell binding, entrance
into the cell cytoplasm via receptor-mediated endocytosis,
replication in tumour cell cytoplasm selectively and inde-
pendently of cell proliferation, proven safety with no serious
side effects, and possibility of used as an adjuvant.27e29
The oncolytic properties of NDV have been studied both
in animal models and humans. Partial to complete regression
of tumours was observed in both cases, even in patients with
advanced tumours who were unresponsive to standard
therapy.30 The occurrence of acute or chronic side effects was
negligible.30,31 In patients suffering from breast or ovarian
cancer, an enhanced survival rate was also noticed.32
Various studies have reported the oncolytic activity of IL-
12-expressingNDVs.33e37Ren andhis colleagues investigated
and compared the antitumoural effect of genetically
engineered NDV strains expressing both IL-12 and/or IL-2
(rClone30einterleukin-2, rClone30einterleukin-12, and
rClone30einterleukin-12einterleukin-2).38 Their study
revealed that rClone30einterleukin-12einterleukin-2 was
more efficiently inhibited hepatoma in mice compared with
either rClone30einterleukin-12 or rClone30einterleukin-2
alone. Another study investigated the immunomodulatory
activity of low titres of NDV AF2240 on human peripheral
blood mononuclear cells (PBMC).38Semliki forest virus (SFV)
SFV is an alphavirus belonging to the family of Toga-
viridae. SFV contains a single positive-strand RNA genome
that replicates in the cytoplasm of infected cells.39 The
genome encodes only nine functional proteins, including
four non-structural proteins that are involved in viral RNA
synthesis, four structural proteins that form the capsid (the C
protein) and the envelope (the E1, E2 and E3 proteins) and a
small 6-kDa protein encoded by the structural region of the
genome that is not incorporated into virions.40,41 As with
many other viruses, the pathogenic characteristics of SFV
have been manipulated to treat diseases rather than cause
them.41 Interestingly, SFV is considered an efficient vector
system to deliver and express transgenes due to its ability
to replicate and grow to a high titre in cultured cells, such
as baby hamster kidney (BHK) cells and chick embryo
cells.41
Various studies have been performed to screen the onco-
lytic properties of SFV.42e44 VA7-SFV, which encodes the
enhanced green fluorescent protein gene (EGFP), is novel
virotherapy candidate against unresectable osteosarcoma, an
aggressive malignant tumour primarily noted in children and
young adults that involves a proliferation of malignant
mesenchymal cells producing immature bone or osteoid.42
Their study demonstrated a profound regression in tumour
size in mice treated with the vector.42 Using a poorly
A.A. Alkayyal et al.190immunogenic MC38 colon adenocarcinoma model to
evaluate the therapeutic potential of SFV vectors,
Rodriguez-Madoz et al. demonstrated that a single intra-
tumoural injection of two IL-12-expressing SFV vectors
(SFV-IL-12 or SFV-enh-IL-12) induced greater than 80%
complete tumour regression with long-term tumour-free
survival.45However, lower doses of SFV-enhIL-12weremore
effective than SFV-IL-12 in inducing antitumoural responses,
demonstrating a positive correlation between the IL-12
expression level and the therapeutic effect.45 Moreover,
repeated intratumoural injections of suboptimal doses of
SFV-enhIL-12 increased the antitumoural response.45
Quetglas et al. also reported that SFV-IL-12 is effective in
the treatment of liver cancer in a murine study, but the effi-
ciency is dependent on a long-term immune response.46Vesicular stomatitis virus (VSV)
VSVs are members of the family Rhabdoviridae and the
prototypes of the Vesiculovirus genus. VSVs are bullet sha-
ped with a genomic structure involving a single strand
negative-sense RNA composed of five genes (N, P, M, G,
and L) representing the nucleocapsid protein, phosphopro-
tein, matrix protein, glycoprotein, and the large protein,
which is a component of the viral RNA polymerase,
respectively.47 The oncolytic activity of VSV toward various
cancers, such as glioma, hepatocellular carcinoma, breast
carcinoma, melanoma and lung cancer, has been
demonstrated in several preclinical tumour models.48e50
The oncolytic strategy of VSV is primarily based on a
defect in the type I IFN response of numerous malignant
tissues.51,52 A disadvantage of the clinical application of
VSV is associated with the potential for neurotoxicity.53,54
This deleterious effect has been observed in many
preclinical studies. However, to overcome this issue,
strategies involving IL-12 combinational therapy are bene-
ficial from a safety prospective. Derek et al., reported that
IL-12 is essential to recover from VSV infection of the mu-
rine central nervous system (CNS).55 This antiviral effect is
mainly mediated by the induction of the neuronal isoform
of nitric oxide synthase (NOS-1) and is independent of the
proinflammatory cytokines IFN-g and TNF-a.55
Shin et al. demonstrated that recombinant VSV vectors
incorporating genes coding for viral fusion protein (rVSV-F)
and interleukin 12 (rVSV-IL12) have significant antitumour
effects against squamous cell carcinoma (SCC) in an ortho-
topic murine model.51 Cultured human andmurine SCC cells
are good platforms for efficient replication of rVSV-F,
whereas normal human and mouse keratinocytes were not
suitable for the vector.51 Injection of multiple doses of the
vectors in a single SCC nodule in mice revealed that
recombinants significantly contribute to the regression of
the tumour and a prolongation of the animal survival.51,52
Using an orthotopic murine SCC model, Shung et al.
assessed the antitumoural activity of a combination of
rVSV-F or rVSV-IL12 with systemic cisplatin (a chemo-
therapy agent), The combination of cisplatin with either VSV
type has a positive effect on the elimination of tumour cells
in vitro.56 In vivo, the addition of cisplatin increased the
antitumoural effect of rVSV-F but hindered the activity of
rVSV-IL12.56Sindbis virus (SINV)
Similar to SFV, SINV is a virus that belongs to the
Togaviridae family.57 SINV is an alphavirus with a genome
composed of a positive single-stranded RNA of approxi-
mately 12 kb that encodes four non-structural and two en-
velope proteins.58 SINV is transmitted by mosquitoes and is
not typically responsible for severe disease in humans.59
Thus, SINV serves as a potential platform for
investigations of cancer treatment through gene therapy
due to the absence of pre-existing neutralizing antibodies.
Another factor that makes SINV a suitable oncolytic agent is
related to the fact that its lifecycle does not involve a DNA
phase, thereby eliminating any risk of genomic integration.60
The mechanism by which SINV targets tumour cells is
thought to involve interactions with the high-affinity lami-
nin receptor, a receptor for SINV in mammalian cells.61 This
receptor is overexpressed in many cancers and makes tumour
cells easy targets for the virus.61 Another advantage of using
SINV in the treatment of cancer is associated with the fact
that the virus is a blood-borne pathogen and can be
administered steadily to target metastatic tumours.60
The oncolytic properties of SINV have been demonstrated
using various cells line and animal models. Using BHK tu-
mours in SCID/beigemice, it was demonstrated that injections
of a SinRep/LacZ vector decreased the size of the tumour
significantly inmice.60Moreover, the same study revealed that
the efficiency of the vector in destroying tumour cells was
enhanced in the presence of NK cells. In addition, a
therapeutic effect of administering IL-12-expressing SINV
vectors has been demonstrated for the treatment of human
ovarian tumours in SCIDmice.60 In addition, Sin/IL12, an IL-
12-carrying SINV vector, has a beneficial effect on the
regression ofmalignant tumours inmice. This vector results in
an increase in the survival time, which is primarily due to IFN-
g-induced NK cell recruitment.60Conclusion
A revolution in molecular and cancer biology has occurred
in recent years that has allowed a better understanding of the
interactions between viruses and host cells. This new under-
standing has also provided an impetus for the development of
cancer treatment by gene therapy that involves the delivery of
specific genes by OVs to efficiently target tumour cells.
Numerous viruses have been investigated for their anti-cancer
properties and appear to be promising in different phases of
clinical trials in humans. Unlike the systemic administration
of recombinant IL-12, IL-12-expressing OVs exhibited no IL-
12-associated organ toxicity. Extensive animal studies on the
use of IL-12-expressing OVs for cancer treatment have clearly
demonstrated a significant antitumour effect of such viruses
that led to partial or complete regression of cancer concom-
itant with an increased survival rate in murine tumour
models. These studies have suggested a model of action
wherein IL-12-expressing OV has multimodal effects: (a)
directly on immune cells, such as cytotoxic T cells, NK cells,
and DCs, and (b) indirectly through IP-10 chemokine in-
duction, which robustly interferes with tumour angiogenesis
(Figure 1). These studies have clearly demonstrated multiple
mechanisms by which IL-12-expressing OVs mediates
Figure 1: Interleukin-12-expressing OVs (OV-IL12) exert multi-
modal antitumoural activity. OVIL12 infects and spreads within
tumour cells, selectively lysing tumour cells and sparing normal
cells. During the viral replication, OV-IL12 releases IL-12 protein,
leading to a direct and indirect cascade of events that modulate the
tumour microenvironment. Direct induction typically occurs in all
immune cells that express IL-12 receptors are noted on the cell
surface of a variety of cells, including NK cells, cytotoxic T cells
(mainly CD8 T cells) and DCs. These three subsets play major
roles in either tumour cell lysis (NK and T cells) or antigen pro-
cessing and presentation (DCs), which further supports the
development of long-term T cell memory. An indirect impact on
the tumour milieu is mainly regulated by IFNg-induced mecha-
nisms that act via several methods on both host and tumour cells
to enhance tumour regression. Effects on the host include the
upregulation of IP-10 chemokine that has a robust antiangiogenic
effect on tumour cells. All together, these multifaceted antineo-
plastic advantages of OV-IL12 viruses induce tumour regression
and ultimately tumour eradication.
Interleukin-12-expressing oncolytic viruses 191tumour protection in several pre-clinical models. Therefore,
an ideal IL-12-expressing OV candidate should have the po-
tential to utilize all of the mechanisms that have been illus-
trated. Therefore, the research focus should be geared toward
the investigation of more combinative therapies, including
immunomodulatory agents, chemotherapy and radiotherapy,
to achieve the optimal benefit.
Conflict of interest
The authors have no conflict of interest to declare.
Authors’ contributions
AAA and ABM contributed equally to this review.References1. Wong HH, Lemoine NR, Wang Y. Oncolytic viruses for cancer
therapy: overcoming the obstacles. Viruses 2010; 2(1): 78e106.
2. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the
first wave of translational clinical trials. Transl Res 2013; 161(4):
355e364.
3. Singh PK, Doley J, Kumar GR, Sahoo AP, Tiwari AK.
Oncolytic viruses & their specific targeting to tumour cells. In-
dian J Med Res 2012; 136(4): 571e584.
4. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral
with cancer immunotherapy.NatRevCancer 2014; 14(8): 559e567.
5. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and
lightning: immunotherapy and oncolytic viruses collide. Mol
Ther 2011; 19(6): 1008e1016.
6. Trinchieri G. Interleukin-12: a cytokine produced by antigen-
presenting cells with immunoregulatory functions in the gener-
ation of T-helper cells type 1 and cytotoxic lymphocytes. Blood
1994; 84(12): 4008e4027.
7. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an
oncolytic herpes virus encoding GM-CSF for unresectable stage
III or IV melanoma. Future Oncol 2010; 6(6): 941e949.
8. Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12: still a
promising candidate for tumor immunotherapy? Cancer
Immunol Immunother 2014; 63(5): 419e435.
9. Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine de-
livery vectors: promises and pitfalls. Expert Opin Biol Ther
2015; 15(3): 337e351.
10. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med
2003; 5(6): 451e462.
11. Crystal RG. Adenovirus: the first effective in vivo gene delivery
vector. Hum Gene Ther 2014; 25(1): 3e11.
12. Seymour LW, Fisher KD. Oncolytic viruses: finally delivering.
Br J Cancer 2016; 114(4): 357e361.
13. Heise C, Kirn DH. Replication-selective adenoviruses as
oncolytic agents. J Clin Invest 2000; 105(7): 847e851.
14. Berk AJ. Recent lessons in gene expression, cell cycle control,
and cell biology from adenovirus. Oncogene 2005; 24(52):
7673e7685.
15. Zhang W, Cai R, Luo J, Wang Y, Cui Q, Wei X, et al. The
oncolytic adenovirus targeting to TERT and RB pathway
induced specific and potent anti-tumor efficacy in vitro and
in vivo for hepatocellular carcinoma. Cancer Biol Ther 2007;
6(11): 1726e1732.
16. Barker DD, Berk AJ. Adenovirus proteins from both E1B
reading frames are required for transformation of rodent cells
by viral infection and DNA transfection. Virology 1987; 156(1):
107e121.
17. Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J,
Graham FL. Intratumoral coinjection of adenoviral vectors
expressing IL-2 and IL-12 results in enhanced frequency of
regression of injected and untreated distal tumors. Gene Ther
1998; 5(10): 1400e1409.
18. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH,
Lee MG, et al. Therapeutic and tumor-specific immunity
induced by combination of dendritic cells and oncolytic
adenovirus expressing IL-12 and 4-1BBL. Mol Ther 2010;
18(2): 264e274.
19. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, et al.
Adenovirus-mediated interleukin-12 gene therapy for prostate
cancer: suppression of orthotopic tumor growth and pre-
established lung metastases in an orthotopic model. Gene
Ther 1999; 6(3): 338e349.
20. Whitley RJ. Herpesviruses. In: Baron S, editor. Medical
microbiology. 4th ed. 1996. Galveston (TX).
21. Homa FL, Brown JC. Capsid assembly and DNA packaging in
herpes simplex virus. Rev Med Virol 1997; 7(2): 107e122.
A.A. Alkayyal et al.19222. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT,
Knowles S, et al. VSV strains with defects in their ability to
shutdown innate immunity are potent systemic anti-cancer
agents. Cancer Cell 2003; 4(4): 263e275.
23. Cassady KA, Parker JN. Herpesvirus vectors for therapy of
brain tumors. Open Virol J 2010; 4: 103e108.
24. Todo T. Active immunotherapy: oncolytic virus therapy using
HSV-1. Adv Exp Med Biol 2012; 746: 178e186.
25. Diel DG, Susta L, Cardenas Garcia S, Killian ML,
Brown CC, Miller PJ, et al. Complete genome and clinico-
pathological characterization of a virulent Newcastle disease
virus isolate from South America. J Clin Microbiol 2012;
50(2): 378e387.
26. Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P.
Newcastle disease virus V protein is a determinant of host range
restriction. J Virol 2003; 77(17): 9522e9532.
27. Cantin C, Holguera J, Ferreira L, Villar E, Munoz-Barroso I.
Newcastle disease virus may enter cells by caveolae-mediated
endocytosis. J Gen Virol 2007; 88(Pt 2): 559e569.
28. Ravindra PV, Tiwari AK, Ratta B, Chaturvedi U, Palia SK,
Subudhi PK, et al. Induction of apoptosis in Vero cells by
Newcastle disease virus requires viral replication, de-novo
protein synthesis and caspase activation. Virus Res 2008;
133(2): 285e290.
29. Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T,
Flechtenmacher J, et al. Newcastle disease virus-infected intact
autologous tumor cell vaccine for adjuvant active specific
immunotherapy of resected colorectal carcinoma. Clin Cancer
Res 1996; 2(1): 21e28.
30. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E,
Rasooly L, Greenbaum E, et al. Phase I/II trial of intravenous
NDV-HUJ oncolytic virus in recurrent glioblastoma multi-
forme. Mol Ther 2006; 13(1): 221e228.
31. Lam HY, Yeap SK, Rasoli M, Omar AR, Yusoff K,
Suraini AA, et al. Safety and clinical usage of Newcastle disease
virus in cancer therapy. J Biomed Biotechnol 2011; 2011:
718710.
32. Haas C, Strauss G, Moldenhauer G, Iorio RM,
Schirrmacher V. Bispecific antibodies increase T-cell stimula-
tory capacity in vitro of human autologous virus-modified tu-
mor vaccine. Clin Cancer Res 1998; 4(3): 721e730.
33. Buijs P, van Nieuwkoop S, Vaes V, Fouchier R, van Eijck C,
van den Hoogen B. Recombinant immunomodulating lento-
genic or mesogenic oncolytic Newcastle disease virus for treat-
ment of pancreatic adenocarcinoma. Viruses 2015; 7(6): 2980e
2998.
34. Janke M, Peeters B, Zhao H, de Leeuw O, Moorman R,
Arnold A, et al. Activation of human T cells by a tumor vaccine
infected with recombinant Newcastle disease virus producing
IL-2. Int J Oncol 2008; 33(4): 823e832.
35. Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A,
Fournier P, et al. Recombinant Newcastle disease virus (NDV)
with inserted gene coding for GM-CSF as a new vector for
cancer immunogene therapy. Gene Ther 2007; 14(23): 1639e
1649.
36. Niu Z, Bai F, Sun T, Tian H, Yu D, Yin J, et al. Recombinant
Newcastle disease virus expressing IL15 demonstrates prom-
ising antitumor efficiency in melanoma model. Technol Cancer
Res Treat 2015; 14(5): 607e615.
37. Susta L, Cornax I, Diel DG, Garcia SC, Miller PJ, Liu X, et al.
Expression of interferon gamma by a highly virulent strain of
Newcastle disease virus decreases its pathogenicity in chickens.
Microb Pathog 2013; 61e62: 73e83.
38. Ren G, Tian G, Liu Y, He J, Gao X, Yu Y, et al. Recombinant
Newcastle disease virus encoding IL-12 and/or IL-2 as potential
candidate for hepatoma carcinoma therapy. Technol Cancer Res
Treat 2015. http://dx.doi.org/10.1177/1533034615601521.39. Jose J, Snyder JE, Kuhn RJ. A structural and functional
perspective of alphavirus replication and assembly. Future
Microbiol 2009; 4(7): 837e856.
40. Strauss JH, Strauss EG. The alphaviruses: gene expression,
replication, and evolution. Microbiol Rev 1994; 58(3): 491e
562.
41. Atkins GJ, Sheahan BJ, Liljestrom P. The molecular patho-
genesis of Semliki forest virus: a model virus made useful? J Gen
Virol 1999; 80(Pt 9): 2287e2297.
42. Ketola A, Hinkkanen A, Yongabi F, Furu P, Maatta AM,
Liimatainen T, et al. Oncolytic Semliki forest virus vector as a
novel candidate against unresectable osteosarcoma. Cancer Res
2008; 68(20): 8342e8350.
43. Autio KP, Ruotsalainen JJ, Anttila MO, Niittykoski M,
Waris M, Hemminki A, et al. Attenuated Semliki forest virus
for cancer treatment in dogs: safety assessment in two labora-
tory Beagles. BMC Vet Res 2015; 11: 170.
44. Vaha-Koskela MJ, Le Boeuf F, Lemay C, De Silva N,
Diallo JS, Cox J, et al. Resistance to two heterologous neuro-
tropic oncolytic viruses, Semliki forest virus and vaccinia virus,
in experimental glioma. J Virol 2013; 87(4): 2363e2366.
45. Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus
vectors engineered to express higher IL-12 levels induce efficient
elimination of murine colon adenocarcinomas. Mol Ther 2005;
12(1): 153e163.
46. Quetglas JI, Rodriguez-Madoz JR, Bezunartea J, Ruiz-
Guillen M, Casales E, Medina-Echeverz J, et al. Eradication of
liver-implanted tumors by Semliki forest virus expressing IL-12
requires efficient long-term immune responses. J Immunol 2013;
190(6): 2994e3004.
47. Letchworth GJ, Rodriguez LL, Del cbarrera J. Vesicular sto-
matitis. Vet J 1999; 157(3): 239e260.
48. Barber GN. Vesicular stomatitis virus as an oncolytic vector.
Viral Immunol 2004; 17(4): 516e527.
49. Li Q, Wei YQ, Wen YJ, Zhao X, Tian L, Yang L, et al. In-
duction of apoptosis and tumor regression by vesicular sto-
matitis virus in the presence of gemcitabine in lung cancer. Int J
Cancer 2004; 112(1): 143e149.
50. Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis
virus: re-inventing the bullet. Trends Mol Med 2004; 10(5): 210e
216.
51. Shin EJ, Chang JI, Choi B, Wanna G, Ebert O, Genden EM,
et al. Fusogenic vesicular stomatitis virus for the treatment of
head and neck squamous carcinomas. Otolaryngol Head Neck
Surg 2007; 136(5): 811e817.
52. Shin EJ, Wanna GB, Choi B, Aguila 3rd D, Ebert O,
Genden EM, et al. Interleukin-12 expression enhances vesicular
stomatitis virus oncolytic therapy in murine squamous cell
carcinoma. Laryngoscope 2007; 117(2): 210e214.
53. van den Pol AN, Dalton KP, Rose JK. Relative neurotropism
of a recombinant rhabdovirus expressing a green fluorescent
envelope glycoprotein. J Virol 2002; 76(3): 1309e1327.
54. Bi Z, Barna M, Komatsu T, Reiss CS. Vesicular stomatitis virus
infection of the central nervous system activates both innate and
acquired immunity. J Virol 1995; 69(10): 6466e6472.
55. Ireland DD, Palian BM, Reiss CS. Interleukin (IL)-12 re-
ceptor beta1 or IL-12 receptor beta 2 deficiency in mice in-
dicates that IL-12 and IL-23 are not essential for host
recovery from viral encephalitis. Viral Immunol 2005; 18(2):
397e402.
56. Sung CK, Choi B, Wanna G, Genden EM, Woo SL,
Shin EJ. Combined VSV oncolytic virus and chemotherapy
for squamous cell carcinoma. Laryngoscope 2008; 118(2):
237e242.
57. Assuncao-Miranda I, Cruz-Oliveira C, Da Poian AT. Molecu-
lar mechanisms involved in the pathogenesis of alphavirus-
induced arthritis. Biomed Res Int 2013; 2013: 973516.
Interleukin-12-expressing oncolytic viruses 19358. Laine M, Luukkainen R, Toivanen A. Sindbis viruses and other
alphaviruses as cause of human arthritic disease. J Intern Med
2004; 256(6): 457e471.
59. Go YY, Balasuriya UB, Lee CK. Zoonotic encephalitides caused
by arboviruses: transmission and epidemiology of alphaviruses
and flaviviruses. Clin Exp Vaccine Res 2014; 3(1): 58e77.
60. Granot T, Venticinque L, Tseng JC, Meruelo D. Activation of
cytotoxic and regulatory functions of NK cells by Sindbis viral
vectors. PLoS One 2011; 6(6): e20598.61. Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH. High-af-
finity laminin receptor is a receptor for Sindbis virus in
mammalian cells. J Virol 1992; 66(8): 4992e5001.
How to cite this article: Alkayyal AA, Mahmoud AB,
Auer RC. Interleukin-12-expressing oncolytic virus: A
promising strategy for cancer immunotherapy. J Taibah
Univ Med Sc 2016;11(3):187e193.
